Genomic mutation-driven metastatic breast cancer therapy: a single center experience

BACKGROUND: Next-Generation Sequencing (NGS) has made genomic mutation-driven therapy feasible for metastatic breast cancer (MBC) patients. We frequently submit tumor tissue from MBC patients for targeted NGS of tumor using the Illumina HiSeq 2000 platform (FoundationOne®, Foundation Medicine, MA)....

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Yuan, Yuan, Yost, Susan E., Yuan, Yate-Ching, Solomon, Nicola M., Mambetsariev, Isa, Pal, Sumanta, Frankel, Paul, Salgia, Ravi, Neuhausen, Susan L., Mortimer, Joanne
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2017
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5432268/
https://ncbi.nlm.nih.gov/pubmed/28061482
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14476
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller